Rapid Micro Biosystems (RPID)
Automates microbial quality-control workflows for pharmaceutical, medical-device, and personal-care manufacturing.
Something off on this page? Send us feedback.
Growth Direct automates microbial quality-control workflows for pharmaceutical, medical-device, and personal-care manufacturers. The platform is sold with proprietary consumables, software, and related services from a Massachusetts base.
Growth Direct is an automated microbial quality-control platform for pharmaceutical, medical-device, and personal-care manufacturing. It detects and quantifies microbial growth by combining sensitive-camera imaging with the cells’ natural autofluorescence, automating manual quality-control workflows. The company sells Growth Direct systems, proprietary consumables, LIMS-connection and other software, and related services.
Headquartered in Lexington, Massachusetts, with U.S. manufacturing in Lowell, it supports manufacturers that need microbial analysis in quality control. Operations have been funded by product and service revenue, equity financing, and borrowing, while the company has reported recurring losses and operating cash outflows since inception.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 22, 2026 | Lake Street | Reiterate | Rating: —Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $19.8M · Total debt $23.5M · Total assets $58.5M · Shareholders' equity $17.7M
- Revenue
- $8.1M
- Operating income
- −$12.3M
- Net income
- −$12.9M
No dividends on record.
| Institutions | 34.94% | 17.52M shares | |
|---|---|---|---|
| 34 holders · as of Jun 30, 2026 | |||
| Insiders | 8.30% | 4.16M shares | |
| 9 holders · as of Jul 24, 2026 | |||
| Strategic holders | 7.04% | 3.53M shares | |
| 1 holder · as of May 15, 2026 | |||
| Other | 49.72% | 24.95M shares | |
| remainder | |||
50.16M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (50.16M in the company's Sep 22, 2026 report, 45.32M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Bain Capital Life Sciences Investors, LLCInstitution | 16.82% | 8.43M A | as of Jun 30, 2026 |
Bain Capital Life Sciences Fund, L.P.Institution | 15.25% | 7.65M | filed Feb 14, 2022 |
Longitude Capital Partners II, LLC1Strategic10 percent owner | 7.04% | 3.53M A | filed May 15, 2026 |
Armistice Capital, LLCInstitution | 6.63% | 3.33M A | as of Jun 30, 2026 |
Robert G. Jr. Spignesi2Insiderdirector, officer: PRESIDENT AND CEO | 5.70% | 2.65M A | filed Jul 24, 2026 |
- Longitude Capital Partners II, LLC's transaction reports restate only vehicles that traded; the 2026 ownership statement (3.53M) is used instead.
- Robert G. Jr. Spignesi's transaction reports restate only vehicles that traded; the 2025 ownership statement (2.65M) plus the 213.5K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | +4,389,000 | $1.44 |
| Mar 10, 2026 | Robert G. Jr. Spignesi | director, officer: PRESIDENT AND CEO | −17,922 | $4.11 |
| Mar 11, 2026 | Sean M. Wirtjes | officer: CHIEF FINANCIAL OFFICER | −7,480 | $4.32 |
| Mar 11, 2026 | John J. Addington Wilson | officer: CHIEF OPERATING OFFICER | −9,603 | $4.32 |
| Feb 19, 2026 | Robert G. Jr. Spignesi | director, officer: PRESIDENT AND CEO | −38,327 | $3.89 |
- Charles River Laboratories
Rapid microbial detection for pharmaceutical and personal-care QC
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Rapid Micro Biosystems | $1.18 | +2.16% | $51.2M | — | — | 1.5 | +10.9% |
| Charles River Laboratories | $285.11 | +0.05% | $13.44B | — | 23.1 | 3.4 | −2.7% |
| Median | — | 23.1 | 3.4 | −2.7% |